Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib vs Best Available Therapy in High Risk Polycythemia Vera
NCT04116502Phase 3Recruiting
- Sponsor
- University of Birmingham
- Start
- Oct 2019
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ruxolitinib in polycythemia vera (PV), sponsored by University of Birmingham. Started Oct 2019; status: recruiting.
02
Drugs
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT04116502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04116502.